

Subscribe to gain insight and stay ahead of emerging trends

Subscribe at cas.org/insights



Insight Reports



Articles



Journal Publications

Topics:

Drug Discovery
Sustainability

Emerging Science
Intellectual Property

Consumer Goods
Synthetic Chemistry

Digital R&D
Biotechnology

Safety
Materials



facebook.com/CAS



linkedin.com/company/cas



[@CASchemistry](https://twitter.com/CASchemistry)





EMERGING TRENDS TO WATCH IN 2024: WEBINAR

From novel therapies, AI, materials, energy, & more...

© 2024 American Chemical Society. All rights reserved.



CAS connects the world's science

At CAS, our passion is advancing scientific progress.

We are proud to partner with innovators across industries, enabling them to maximize the power of connected scientific information to advance discovery and get solutions to market faster.

BETWEEN PROBLEMS AND PROGRESS
ARE CONNECTIONS THAT MATTER



CAS connects you to the world's published science for better insights



Over
50K
scientific journals
and documents

Over
250
million substances

Over
50
languages
translated

109
patent offices
worldwide

Introductions



Dr. Jonathan Allen

Informaticist team lead for small molecule drug discovery with AI/ ML at


Lawrence Livermore National Laboratory



Dr. Arnold Lumsdaine

Director of Innovation (INFUSE)

Oak Ridge National Lab



Dr. Yiying Wu

Professor of Chemistry specializing in energy storage and batteries

The Ohio State University



Janet Sasso

Information Scientist specializing in life sciences and biotechnology

CAS



Dr. Kevin Hughes

Information scientist specializing in materials science and applied physics

CAS



Dr. Angela Zhou

Manager scientific insight and analysis

Moderator

CAS

TACKLING THE UNDRUGGABLES

Advancements and Emerging Trends


Janet Sasso, Information Scientist, CAS

© 2024 American Chemical Society. All rights reserved.




Alzheimer's disease and emerging trends

Anti-amyloid agents




Alzheimer's disease and emerging trends

Anti-amyloid agents




Alzheimer's disease and emerging trends

Anti-amyloid agents




Alzheimer's disease and emerging trends

Anti-amyloid agents





Parkinson's disease and biomarker validation

Alpha-Synuclein





Parkinson's disease and biomarker validation

Alpha-Synuclein




Antibody-drug conjugate (ADC)

Targeted Immunotherapy



ADC Publication Trends

50x increase in patent publications since 1990s



Global patent trend for ADCs from 1990 to 2022 (CAS Content Collection™)

Trends


- Despite a pandemic, explosive growth of publications since first FDA approved ADC in 2000
- Nearly 30% increase in patents alone from 2020 onward

Oncology is leading the clinical pipeline

Expanding efforts to fill gaps left by conventional drugs

Trends

- Breast cancer and autoimmune disease lead paper publications
- Latest FDA ADC approvals target ovarian, head and neck, cervical, and gastric cancers.
- Outside of oncology, ADCs in clinical trials are exploring the treatment of autoimmune disorders and amyloidosis



Gain insights on emerging 2024 trends and more



Janet Sasso

Information Scientist
jsasso@cas.org

CAS Insights article
cas.org/trends



Articles



Executive Summaries



Insight Reports



Journal Publications

Subscribe to stay connected and follow us on:



facebook.com/CAS



linkedin.com/company/cas

 [@CASchemistry](https://twitter.com/CASchemistry)



AI/ML developments in drug discovery



Jonathan Allen, Ph.D.
Informatics Scientist
allen99@llnl.gov

January 25, 2024




Adding AI/ML decision making to drug discovery


Traditional computational drug discovery approach



Experimental feedback



Manually selected protein target




3) Intelligent search of chemical space


2) Accurate, comprehensive drug property scoring

1) Flexible on/off target selection for potency models


100+ billion screening compounds Paradigm shift




Model Driven Experimental feedback



Improved active learning workflows



Recent example of automated iterative chemical synthesis



Koscher et al., 2023: <https://www.science.org/doi/10.1126/science.adi1407>

Limited examples of clinical success with signs of potential



- A handful of examples of Investigational New Drug (IND) filings with early clinical trials
 - These are small molecules
- More examples of de novo drug design showing on target potency and promising pharmacokinetic/safety profiles
 - Likely still challenges with modeling complexity in human biology
 - Potential improvements with better omics measurements to stratify patient population
- Antibody redesign to restore potency is generating impact
 - De novo design still requires further work
- Improvements in protein folding prediction are opening up potential for new de novo biologics design
 - Added potential for peptide design




Disclaimer

This document was prepared as an account of work sponsored by an agency of the United States government. Neither the United States government nor Lawrence Livermore National Security, LLC, nor any of their employees makes any warranty, expressed or implied, or assumes any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product, or process disclosed, or represents that its use would not infringe privately owned rights. Reference herein to any specific commercial product, process, or service by trade name, trademark, manufacturer, or otherwise does not necessarily constitute or imply its endorsement, recommendation, or favoring by the United States government or Lawrence Livermore National Security, LLC. The views and opinions of authors expressed herein do not necessarily state or reflect those of the United States government or Lawrence Livermore National Security, LLC, and shall not be used for advertising or product endorsement purposes.


Traditional chemical search methods do not scale well




EN300-89728



EN300-27230



EN300-345189



EN300-383280




EN300-106635



Chemical building blocks
for compound synthesis

**100K+ building blocks ad
growing!**

Generative molecular models similar to models in other domains




Generative chemical model search larger chemical spaces





Disclaimer

This document was prepared as an account of work sponsored by an agency of the United States government. Neither the United States government nor Lawrence Livermore National Security, LLC, nor any of their employees makes any warranty, expressed or implied, or assumes any legal liability or responsibility for the accuracy, completeness, or usefulness of any information, apparatus, product, or process disclosed, or represents that its use would not infringe privately owned rights. Reference herein to any specific commercial product, process, or service by trade name, trademark, manufacturer, or otherwise does not necessarily constitute or imply its endorsement, recommendation, or favoring by the United States government or Lawrence Livermore National Security, LLC. The views and opinions of authors expressed herein do not necessarily state or reflect those of the United States government or Lawrence Livermore National Security, LLC, and shall not be used for advertising or product endorsement purposes.

A person with dark skin and dreadlocks is shown in profile, wearing a blue shirt and a head-mounted display (HMD) with a silver band across the forehead. The background is a blurred indoor setting with a plant on the left and a window on the right. A large white geometric shape, resembling a stylized 'A' or a house, is overlaid on the left side of the image, containing the main text.

INNOVATION AT THE INTERSECTION OF BIOMEDICINE AND MATERIALS SCIENCE

A quantitative review of emerging trends

Kevin Hughes, Information Scientist, CAS

© 2024 American Chemical Society. All rights reserved.

CAS

A division of the
American Chemical Society



Identifying top growing trends in biomaterials

Through quantitative data analytics

Key take-aways:


- Innovation is often found at the intersection of disciplines

Identifying top growing trends in biomaterials

Through quantitative data analytics

Key take-aways:

- Innovation is often found at the intersection of disciplines




Choi, Y. S., et al. Stretchable, dynamic covalent polymers for soft, long-lived bioresorbable electronic stimulators designed to facilitate neuromuscular regeneration. *Nature Communications* **2020**, 11 (1), 5990

Identifying top growing trends in biomaterials

Through quantitative data analytics

Key take-aways:

- Innovation is often found at the intersection of disciplines
- Goal of this analysis: provide data-based support for decision making and R&D planning



Choi, Y. S., et al. Stretchable, dynamic covalent polymers for soft, long-lived bioresorbable electronic stimulators designed to facilitate neuromuscular regeneration. *Nature Communications* **2020**, 11 (1), 5990



Identifying Emerging Trends

Natural Language Processing (NLP) with SME guidance on large data sets

Query CAS Content Collection
to select journal and patent
publications in biomaterials






Natural Language
Processing (NLP)
to identify concepts



Identifying Emerging Trends

Natural Language Processing (NLP) with SME guidance on large data sets




NLP-identified concepts also scored using:

- Publication rate
- Relative growth rate
- Citations

Identifying Emerging Trends

Natural Language Processing (NLP) with SME guidance on large data sets



Eight key areas emerged in 3 key categories

Fastest areas of growth, validated by SME expertise into data

Eight key areas emerged in 3 key categories

Fastest areas of growth, validated by SME expertise into data

Material Functions

- Programmable biomaterials
- Self healing biomaterials

Eight key areas emerged in 3 key categories

Fastest areas of growth, validated by SME expertise into data

Material Functions

- Programmable biomaterials
- Self healing biomaterials

Compositions

- Protein based materials
- Lipid based materials

Eight key areas emerged in 3 key categories

Fastest areas of growth, validated by SME expertise into data

Material Functions

- Programmable biomaterials
- Self healing biomaterials

Compositions


- Protein based materials
- Lipid based materials

Applications

- Bioinks
- Bioelectronic materials
- Antibiotic materials
- Sustainable alternatives for biomedical materials

Programmable biomaterials

Stimulus type is a key aspect




Azam, A., et al. Self-folding micropatterned polymeric containers. *Biomed Microdevices* **2011**, 13(1), 51-58

Programmable biomaterials

Stimulus type is a key aspect

Trend Analysis:

- pH and magnetic stimuli appear more prominently in journal publications
- Mechanical and temperature-based stimuli appear relatively more in patents



For more details visit cas.org/biomaterials



Dr. Kevin Hughes
Information Scientist
khughes@cas.org



Articles



Executive Summaries



Insight Reports



Journal Publications



Subscribe to be the first to know about Phase 2's publication:



facebook.com/CAS



linkedin.com/company/cas



[@CASchemistry](https://twitter.com/CASchemistry)

Trends in Battery Energy Storage

Yiying Wu

Department of Chemistry & Biochemistry
The Ohio State University
Columbus, Ohio



Fifty years of lithium-ion batteries and what is next?

M. Stanley Whittingham*^{ID} and Jie Xiao

– *MRS Bulletin* 48, 1118–1124 (2023).



Cell Chemistry

- Li metal anode.
- Solid-state batteries.
- Sodium and potassium-based batteries.
- Extreme Conditions.
- Sulfur batteries.
- Oxygen batteries


Beyond the Cell Chemistry

- - Manufacturing technologies for batteries: reducing energy consumption and transportation costs.
- - Regional supply chains and clean mining with renewable energy.
- - From Cradle to Cradle: Recycling for reducing waste and recovering materials from end-of-life batteries.
- - Safety is a big concern, and overdesigning safety into materials and systems is necessary.

Nuclear Fusion Energy


Arnold Lumsdaine
Director, Innovation Network for Fusion
Energy (INFUSE)
Oak Ridge National Lab

January 25, 2024



ORNL is managed by UT-Battelle, LLC for the US Department of Energy

The Future of Our Civilization Depends on Energy



- Projected need for $\sim 35,000$ GW from non-CO₂ producing sources




35,000 1 GW-e plants !!!

- By 2050, annual global energy investment would need to reach \$0.66 T (\$23 T cumulative)
 - GDP (2018): US: \$21T, China: \$14T, UK: \$2.9T
 - Global cell phone market: \$0.55 T


A New Era in Fusion Energy Development Has Dawned

Confluence of developments have positioned fusion for a major 20-year push

- Achievements on National Ignition Facility and Joint European Torus demonstrate fusion energy production
- Multiple reports for U.S. expert groups indicate readiness and urgency of fusion development
- Extensive predictive tools for optimizing performance now in place
- New technologies available to address key challenges
 - Superconductors, Materials by Design, Advanced Manufacturing, High Performance Computing
- Significant escalation in investment in clean energy
→ new \$\$\$ to make push possible




The National Academies says that it's time




NAE (2017)

Identified “Provide energy from fusion” as a grand challenge for the 21st century



NASEM (2018)


“Now is the right time for the United States to develop plans to benefit from its investment in burning plasma research and take steps towards the development of fusion electricity for the nation’s future energy needs”



NASEM (2021)

“Successful operation of a pilot plant in the 2035–2040 timeframe requires urgent investments by DOE and private industry—both to resolve the remaining technical and scientific issues and to design, construct, and commission a pilot plant.”

Private investment in fusion has surged in recent years



Currently over \$6B invested

<https://www.fusionindustryassociation.org/news/from-the-fia/#industry-reports>



US government has announced a decadal initiative to develop fusion energy

White House Summit on Developing a Bold Decadal Vision for Commercial Fusion Energy

“Fusion is a potential carbon-free, abundant source of clean energy that will bolster American leadership, strengthen energy security, and enable sustained energy independence”



Rep.
Chuck
Fleischmann
(TN)

US ITER Project
Director Kathy
McCarthy speaking
during the White
House summit on
March 17, 2022



Department of Energy Focus on Public-Private Partnerships

INFUSE program

- Enables private firms to tap into national lab and university resources to address key issues
 - Led by ORNL and PPPL <https://infuse.ornl.gov/>



11 Participating DOE labs




Fusion Industry Association




Milestone Program

- In 2023, the DOE Office of Fusion Energy Sciences launched a milestone-based fusion development program, with \$46M for private companies (with 50% cost share) towards the development of fusion power with completion of preliminary design expected within 5 years.
- Eight awards were announced:
 - Commonwealth Fusion Systems
 - Focused Energy, Inc.
 - Realta Fusion
 - Thea Energy
 - Tokamak Energy
 - Type One Energy
 - Xcimer Energy Corporation
 - Zap Energy


Generating Electricity from Fusion Energy Requires Meeting Three Scientific/Technological Challenges




Generating Electricity from Fusion Energy Requires Meeting Three Scientific/Technological Challenges




Generating Electricity from Fusion Energy Requires Meeting Three Scientific/Technological Challenges



Technical readiness must be advanced rapidly to meet ambitious timelines for fusion implementation





Materials challenges are complex involving multiple extremes




Fusion Facilities in the Next Decade


- **ITER** is a 35-nation collaboration under construction in Cadarache, France, and is expected to produce 500 MW fusion power for 400s, and begin operation in the 2030's.
- The **MPEX** project will support the development of candidate plasma facing materials and is currently under construction, with operation expected in early 2028.
- A **Fusion Prototypic Neutron Source** has been identified by the fusion community as a critical next facility to fill critical material science gap for exposure to fusion neutrons.



Multibeam D⁺ into T gas target fusion neutron source



**D – Li stripping reaction
~5 MW D accelerator and liquid Li target**



Gain insight at the intersection of science, tech and innovation

Connect with us at cas.org/insights



Insight Reports



Articles



Journal Publications

Topics:

Drug Discovery
Sustainability

Emerging Science
Intellectual Property

Consumer Goods
Synthetic Chemistry

Digital R&D
Biotechnology

Safety
Materials



facebook.com/CAS



linkedin.com/company/cas



[@CASchemistry](https://twitter.com/CASchemistry)

